Company Overview and Technology SpyGlass Pharma (sometimes referred to as SpyGlass Bio) is a late-stage ophthalmic biotechnology company focused on

Vaccine royalties have matured into a distinct sub-asset class, driven by blockbuster revenues from HPV, pneumococcal, shingles, and mRNA vaccines.

OpenAI has publicly floated a revenue model in which it would subsidize AI compute for drug discovery firms in exchange

Every royalty transaction carries a map. Before the discount rate is set, before the cap structure is negotiated, before the first dollar changes hands, the most consequential question in pharmaceutical royalty financing is deceptively simple: where does the money come from?

The first week of February 2026 delivered an active transaction period. Four IPOs collectively raised $987 million — the busiest single

How the EU's harmonised clinical assessment framework is changing the mathematics of pharmaceutical royalty underwriting

Overview and Investment Focus Bertelsmann Healthcare Investments (BHI) is a dedicated healthcare venture fund launched in late January 2026 by

What has tiny arms but might revolutionize autoimmune treatment? No, not that T-Rex—this one's all about regulatory T cells, and its reach into immunology is anything but short.

Introduction Arrow declarations have emerged as a distinctive mechanism in patent litigation, particularly within the UK pharmaceutical sector, with significant

Equity kickers—warrants, options, convertible features, or other equity-linked instruments bundled with debt or investment transactions—serve as return enhancers